LOXL2 and neoplasm: Additionally, our findings revealed that patients with triple‐negative breast cancer receiving neoadjuvant chemotherapy showed lower levels of LOX and LOXL2 expression in their tumour tissues than those who were sensitive to taxanes, anthracyclines and platinum agents.